Lowell Therapeutics

0 followers


Lowell Therapeutics is developing a breakthrough product and a company that makes a real difference in the lives of critically ill patients in the ICU. The phase 3 primary endpoint for their product, Niyad, will be met by proving it anti-coagulates blood.

Industries

Headquarters

Stage

Employees

Links

Org chart

James Wilkie
President & CEO

James Wilkie

Collapse
Elaine Liong
VP, Regulatory Affairs
Michelle Merrigan
Clinical Operations